LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program

Rhea-AI Summary

LB Pharmaceuticals (Nasdaq: LBRX) initiated a randomized, double-blind Phase 2 ILLUMINATE-1 trial of oral LB-102 in bipolar 1 depression on Jan 26, 2026. The two-arm, six-week outpatient study will randomize ~320 patients 1:1 to LB-102 (pooled 25 mg or 50 mg once daily) or placebo across ~30 U.S. sites. The primary endpoint is MADRS-10 at week 6 with a primary analysis pooling doses vs placebo. Secondary measures include MADRS-6, CGI-BP, cognition, and anhedonia. Topline results are expected in 1Q 2028. Company also noted prior positive Phase 2 schizophrenia results and a Phase 3 schizophrenia program on track with H2 2027 results expected.

Positive

• Phase 2 initiation for bipolar 1 depression underway
• Planned enrollment of ~320 patients at ~30 U.S. sites
• Topline results expected 1Q 2028, providing a clear clinical timeline
• Phase 3 schizophrenia program on track with results expected H2 2027

Negative

• Long development timeline: pivotal readouts extend into H2 2027–1Q 2028
• Primary analysis pools both doses, which may mask dose-response

News Market Reaction – LBRX

-6.40%

2 alerts

-6.40% News Effect

-$30M Valuation Impact

$441M Market Cap

0.3x Rel. Volume

On the day this news was published, LBRX declined 6.40%, reflecting a notable negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $30M from the company's valuation, bringing the market cap to $441M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Topline data timing: 1Q 2028 Trial phase: Phase 2 Dose levels: 25 mg and 50 mg +5 more

8 metrics

Topline data timing 1Q 2028 Expected for Phase 2 bipolar depression ILLUMINATE-1 trial

Trial phase Phase 2 ILLUMINATE-1 bipolar depression efficacy and safety study

Dose levels 25 mg and 50 mg Once-daily oral LB-102 doses vs placebo

Planned enrollment Approximately 320 patients Bipolar I depression patients in Phase 2 trial

Trial duration Six weeks Outpatient treatment period for Phase 2 ILLUMINATE-1

Study sites Approximately 30 sites U.S. locations participating in bipolar depression trial

Randomization ratio 1:1 LB-102 versus placebo allocation in Phase 2 trial

Primary endpoint MADRS-10 at week six Montgomery–Åsberg Depression Rating Scale total score

Market Reality Check

Price: $25.67 Vol: Volume 125,891 is 50% bel...

low vol

$25.67 Last Close

Volume Volume 125,891 is 50% below the 20-day average of 253,079, suggesting a modest pre-news positioning. low

Technical Price at $23.91 is trading above the 200-day MA of $17.78 and within 2.24% of the 52-week high.

Peers on Argus

Peers show mixed moves: LRMR up 7.58%, ASMB up 1.45%, while ABEO, DRUG, and RCKT...

Peers show mixed moves: LRMR up 7.58%, ASMB up 1.45%, while ABEO, DRUG, and RCKT are down between 2–4%, indicating stock-specific rather than broad biotech momentum for LBRX.

Historical Context

5 past events · Latest: Jan 21 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 21	Executive appointment	Positive	+0.7%	Appointment of experienced General Counsel to support LB-102 and CNS strategy.
Jan 12	Inducement grants	Neutral	+4.0%	Equity option awards to two new senior hires under Nasdaq inducement rules.
Jan 06	Leadership additions	Positive	-3.3%	New senior VPs in Corporate Affairs and People & Culture as LB-102 advances.
Dec 10	Inducement grant	Neutral	-2.8%	Stock option inducement award to new Chief Commercial Officer.
Dec 09	Index inclusion	Positive	-2.3%	Addition to Russell 2000 and 3000 indices following IPO and trial planning.

Pattern Detected

Recent news has been mostly corporate and index-related, with positive announcements sometimes followed by negative price reactions, indicating occasional divergence between news tone and short-term trading.

Recent Company History

Over the past few months, LB Pharmaceuticals has focused on building its organization and market presence, including leadership additions, inducement grants, and index inclusion on Dec 22, 2025. The Q3 2025 10-Q highlighted a strengthened balance sheet post-IPO and described LB‑102 as Phase 3‑ready for acute schizophrenia. Today’s Phase 2 bipolar depression initiation builds on this trajectory by expanding LB‑102 into mood disorders, complementing prior efforts to prepare the pipeline and leadership for late-stage development.

Market Pulse Summary

The stock moved -6.4% in the session following this news. A negative reaction despite the initiation...

Analysis

The stock moved -6.4% in the session following this news. A negative reaction despite the initiation of a Phase 2 bipolar depression trial would fit the pattern where some positive corporate or index developments previously coincided with short-term price declines. Shares were already trading near the 52‑week high at $23.91 and above the $17.78 200‑day MA, so profit-taking around longer timelines into 2027–2028 could amplify downside. Past events show both aligned and divergent moves, underscoring that near-term trading has not always tracked news tone.

Key Terms

randomized, double-blind, placebo-controlled, madrs-10, madrs-6, eps, +3 more

7 terms

randomized, double-blind, placebo-controlled medical

"The Phase 2 trial is a multi-center, randomized, double-blind, placebo-controlled trial"

A "randomized, double-blind, placebo-controlled" process is a method used to test the effectiveness of a new treatment or intervention. Participants are randomly assigned to different groups, with one receiving the real treatment and the other a fake version, called a placebo. Neither the participants nor the researchers know who is receiving which, which helps ensure unbiased results. For investors, this rigorous approach increases confidence that the findings are accurate and not influenced by guesswork or bias.

madrs-10 medical

"The primary endpoint is the Montgomery–Åsberg Depression Rating Scale (MADRS)-10 at week six."

A MADRS-10 is a clinician-rated questionnaire with 10 items used to measure the severity of depressive symptoms; think of it as a standardized “thermometer” for depression. Investors pay attention because it’s commonly used as a primary way to show whether a psychiatric treatment works in clinical trials, and those results can affect regulatory approval, labeling, and commercial prospects—key drivers of a drug’s market value.

madrs-6 medical

"Secondary endpoints include MADRS-6, and CGI-BP, cognition, and anhedonia"

A brief, six-item version of the Montgomery-Åsberg Depression Rating Scale used by clinicians to quantify the severity of core depression symptoms in a patient. Think of it as a short thermometer or checklist that gives a quick, standardized score for how a patient is doing. Investors watch MADRS-6 results because they are often used as trial endpoints that signal whether a psychiatric treatment is working, which can influence regulatory decisions and market value.

eps medical

"reduced side effects such as sedation and EPS (including akathisia), and improvement"

Earnings per share (EPS) measures how much profit a company makes for each outstanding share of its stock by dividing the company’s profit after expenses by the number of shares. It matters to investors because it shows how much of the company’s “pie” each share represents—higher EPS usually signals greater profitability per share, helps compare companies of different sizes, and influences stock valuations and investor decisions.

akathisia medical

"reduced side effects such as sedation and EPS (including akathisia), and improvement"

A movement disorder that makes a person feel an uncontrollable inner restlessness and a strong need to move, often described like an internal motor that prevents sitting still. It most commonly appears as a side effect of certain medications and matters to investors because it can trigger safety warnings, product restrictions, patient complaints or lawsuits, and reduced drug use—factors that can materially affect a company’s revenue and regulatory standing.

anhedonia medical

"and improvement in anhedonia and cognitive deficits, all of which can impact"

Anhedonia is the reduced ability to feel pleasure or interest in things that used to be enjoyable, like hobbies, socializing, or eating; think of it as a dimmer switch turning down the joy in everyday activities. For investors, it matters because anhedonia is a common symptom targeted by drugs, therapies, and diagnostics, so its prevalence and how well treatments address it can affect clinical trial outcomes, regulatory approval prospects, market demand, and a healthcare company's valuation.

5ht7 medical

"selective antagonist of D2, D3, and 5HT7 receptors that is being advanced"

5‑HT7 is a specific type of serotonin receptor in the brain and body that acts like a tiny lock on cells, where certain drugs (the keys) can attach and change how cells behave. It matters to investors because medicines that target this receptor can affect mood, sleep and circadian rhythms, making it a promising drug target; successful drug candidates or trial results can materially affect a biotech or pharmaceutical company’s value.

AI-generated analysis. Not financial advice.

Topline data expected in 1Q 2028

Phase 2 bipolar depression trial initiation follows positive Phase 2 results in acute schizophrenia

NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the initiation of a Phase 2 trial evaluating the efficacy and safety of LB-102 in patients with bipolar depression. LB-102, a novel, once-daily, oral investigational small molecule, is a potent and selective antagonist of D2, D3, and 5HT7 receptors that is being advanced as a potential first benzamide antipsychotic in the U.S. for the treatment of neuropsychiatric disorders.

“Our year is off to a strong start and the initiation of this Phase 2 trial in patients with bipolar depression marks an important step in our strategy to expand the potential of LB-102 for the treatment of mood disorders,” said Heather Turner, Chief Executive Officer of LB Pharmaceuticals. “We believe the compelling results from our Phase 2 trial in acute schizophrenia, the heritage of clinical and real-word experience with amisulpride in the treatment of mood disorders, and our innovative fixed-flexible dose trial design can significantly derisk this program. We look forward to a number of late-stage clinical catalysts, including results from this Phase 2 trial in the first quarter of 2028, as well as from our planned Phase 3 trial in schizophrenia which remains on track to initiate this quarter with results expected in the second half of 2027.”

Anna Eramo, Chief Medical Officer of LB Pharmaceuticals added, “We believe LB-102’s pharmacologic profile, including selective D2, D3, and 5HT7 receptor antagonism and favorable tolerability observed in prior clinical trials, aligns well with the critical unmet needs in bipolar depression. Significant opportunity exists for new therapies that can offer early onset of effect, reduced side effects such as sedation and EPS (including akathisia), and improvement in anhedonia and cognitive deficits, all of which can impact a patient’s ability to function.”

Phase 2 Bipolar Depression ILLUMINATE-1 Trial Design

The Phase 2 trial is a multi-center, randomized, double-blind, placebo-controlled trial with fixed- and flexible-doses and is designed to evaluate the efficacy and safety of two doses (25 mg and 50 mg given once daily) of LB-102 for the treatment of bipolar depression. The two-arm, six-week, outpatient trial is expected to enroll approximately 320 patients with bipolar 1 depression at approximately 30 sites in the U.S. Patients will be randomized 1:1 to receive either LB-102 or placebo. The primary endpoint is the Montgomery–Åsberg Depression Rating Scale (MADRS)-10 at week six. The primary statistical analysis will compare results from all patients receiving LB-102, regardless of dose, with placebo. Secondary endpoints include MADRS-6, and CGI-BP, cognition, and anhedonia, as well as safety and tolerability. Topline results from the trial are anticipated in the first quarter of 2028.

About LB-102

LB-102 is a novel, once-daily, orally administered investigational small molecule and potential first benzamide antipsychotic in the U.S. for the treatment of neuropsychiatric disorders. A methylated derivative of amisulpride, a widely used antipsychotics outside the U.S., LB-102 was developed to retain amisulpride’s benefits while addressing its limitations. LB-102 is a potent and selective antagonist of D2, D3, and 5HT7 receptors with few off-target effects and broad therapeutic potential across psychosis and mood disorders. In early 2025, LB Pharmaceuticals announced positive data from a four-week placebo-controlled, double-blinded, Phase 2 trial in patients with acute schizophrenia. In this trial, LB-102 demonstrated statistically significant benefit versus placebo at all doses studied, including rapid and sustained benefit, a potentially class-leading safety profile with low rates of EPS (including akathisia), minimal sedation and few GI side effects, alongside robust effects on cognition and negative symptoms. These data underscore LB‑102’s potential to address multiple dimensions of neuropsychiatric illness. LB-102 is advancing into a Phase 3 clinical trial for schizophrenia and a Phase 2 clinical trial for bipolar depression has been initiated. Additional expansion opportunities for LB-102 include major depressive disorder, predominantly negative symptoms of schizophrenia, Alzheimer’s disease psychosis and agitation, as well as other neuropsychiatric diseases.

About Bipolar Depression

Bipolar disorder is a chronic, debilitating mood disorder in which patients alternate between manic and depressive states. There are approximately 7 million patients in the U.S. and 40 million patients worldwide suffering from bipolar disorder. Antipsychotic medications, with or without mood stabilizers, are a mainstay of therapy for bipolar depression due to their ability to control depressive symptoms while preventing the emergence of mania. Despite the availability of several branded and generic therapeutics, significant unmet needs remain including faster onset without dose titration, lower rates of adverse events (including extrapyramidal symptoms, sedation, and GI side effects), efficacy against residual symptoms (including anhedonia and cognitive deficits), as well as improved medication adherence. Approximately 60% of patients with bipolar depression experience cognitive impairment and loss of interest/enjoyment (anhedonia) despite treatment, as well as high rates of adverse events, which together contribute to high rates of medication discontinuation and increased risk of relapse.

About LB Pharmaceuticals

LB Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the Company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering a balanced clinical activity and tolerability profile that provides a potentially attractive alternative to branded and generic therapeutics for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.

Cautionary Note Regarding Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” or similar expressions are intended to identify forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning the expected timing of clinical data readouts for the Company’s Phase 2 ILLUMINATE-1 trial in bipolar depression and Phase 3 trial in acute schizophrenia, planned trial design of the Phase 2 ILLUMINATE-1 trial, clinical development and regulatory pathway and therapeutic benefits of LB-102 and continuing advancement of LB-102 and the Company’s portfolio. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: the Company’s limited operating history and historical losses; the Company’s ability to raise additional funding to complete the development and any commercialization of LB-102; the Company’s dependence on the success of its lead product candidate, LB-102; the Company’s ability to obtain regulatory approval of and successfully commercialize its product candidate; the early stages of clinical development of the Company’s lead product candidate, LB-102; any undesirable side effects or other properties of the Company’s product candidate; that the Company may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; the Company’s ability to obtain, maintain and protect its intellectual property; and the Company’s dependence on third parties in connection with manufacturing, clinical trials and preclinical studies.

These and other risks are described more fully in the section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 and its other documents to be subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media and Investor Contact: 
Ellen Rose
erose@lbpharma.us

FAQ

What is the design of LB Pharmaceuticals' ILLUMINATE-1 Phase 2 trial for bipolar depression (LBRX)?

The trial is a multi-center, randomized, double-blind, placebo-controlled, two-arm six-week study randomizing ~320 bipolar 1 patients 1:1 to LB-102 (25 mg or 50 mg once daily) or placebo.

When does LB Pharmaceuticals (LBRX) expect topline results from the Phase 2 bipolar depression trial?

Topline results are anticipated in first quarter 2028.

What is the primary endpoint of the LB-102 bipolar depression Phase 2 trial (LBRX)?

The primary endpoint is the MADRS-10 score at week 6, with the primary analysis comparing all LB-102 recipients pooled versus placebo.

What doses of LB-102 are being tested in the ILLUMINATE-1 trial (LBRX)?

Two once-daily oral doses are being evaluated: 25 mg and 50 mg.

How does the LB-102 program timeline relate to the company's schizophrenia program (LBRX)?

Company expects its Phase 3 schizophrenia trial to initiate this quarter with results targeted in H2 2027, preceding the bipolar Phase 2 topline in 1Q 2028.